Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-09
2006-05-09
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S019300
Reexamination Certificate
active
07041639
ABSTRACT:
Depsipeptides and congeners thereof are disclosed having the following structure:wherein m, n, p, q, X, R1, R2and R3are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.
REFERENCES:
patent: 4268516 (1981-05-01), Lombardino et al.
patent: 4977138 (1990-12-01), Okuhara et al.
patent: 5294603 (1994-03-01), Rinehart
patent: 5591717 (1997-01-01), Rojko et al.
patent: 5843943 (1998-12-01), Carson et al.
patent: 5891653 (1999-04-01), Attfield
patent: 5942229 (1999-08-01), Noelle et al.
patent: 6211145 (2001-04-01), Yanai et al.
patent: 6252041 (2001-06-01), Yanai et al.
patent: 6265537 (2001-07-01), Jeschke et al.
patent: 6316406 (2001-11-01), Yanai et al.
patent: 352 646 (1993-06-01), None
patent: 931 544 (1999-07-01), None
patent: WO 93/19778 (1993-10-01), None
patent: WO 95/33823 (1995-12-01), None
patent: WO 97/35990 (1997-10-01), None
patent: WO 98/39412 (1998-09-01), None
patent: WO 98/46640 (1998-10-01), None
patent: WO 99/11659 (1999-03-01), None
patent: WO 99/14241 (1999-03-01), None
patent: WO 99/15174 (1999-04-01), None
patent: WO 99/20296 (1999-04-01), None
patent: WO 99/25703 (1999-05-01), None
patent: WO 99/30730 (1999-06-01), None
patent: WO 99/51731 (1999-10-01), None
Bates, S. et al., “A Phase I Study ofFR901228 (Depsipeptide), a Histone Deacetylase Inhibitor,” proceedings of the 1999 ASCO Annual Meeting, retrieved Feb. 10, 2005, from http://www.asco.org/ac/1,1003,—12-002640-00—18-0017-00—19-0014945,00.asp, 2 pages.
Agrawal and Reynolds, “An Evaluation of the Mitogenic Reactivity of Intestinal Intraepithelial Lymphocytes of Chickens,”Avian Diseases 43:172-181, 1999.
Aramburu et al., “Affinity-Driven Peptide Selection of an NFAT Inhibitor More Selective Than Cyclosporin A,”Science 285:2129-2133, Sep. 24, 1999.
Bierer et al., “Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology,”Current Opinion in Immunology 5:763-773, 1993.
Blyth et al., “Lung Inflammation and Epithelial Changes in a Murine Model of Atopic Asthma,”Am. J. Respir. Cell Mol. Biol. 14:425-438, 1996.
Böhmig et al., “n-Butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids,”Immunology 92:234-243, 1997.
Bonneville et al., “Self-tolerance to transgenic γδ T cells by intrathymic inactivation,”Nature 344:163-165, Mar. 8, 1990.
Bottazzo et al., “In Situ Characterization of Autoimmune Phenomena and Expression of HLA Molecules in the Pancreas in Diabetic Insulitis,”The New England Journal of Medicine 313(6): 353-360, Aug. 8, 1985.
Byrd et al., “Depsipeptide (FR901228): A Novel Therapeutic Agent With Selective, In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells,”Blood 94(4): 1401-1408, Aug. 15, 1999.
Cantrell and Smith, “The Interleukin-2 T-Cell System: A New Cell Growth Model,”Science 224:1312-1316, Jun. 22, 1984.
Chan et al., “Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS,”Investigational New Drugs 15:195-206, 1997.
Chassaing et al., “Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phases,”Journal of Chromatography B 719:169-176, 1998.
Dangond et al., “Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PH-Activated Immune Cells,”Biochemical and Biophysical Research Communications 242:648-652, 1998.
Dangond and Gullans, “Differential Expression of Human Histone Deacetylase mRNAs in Response to Immune Cell Apoptosis Induction by Trichostatin A and Butyrate,”Biochemical and Biophysical Research Communications 247:833-837, 1998.
Dengler et al., “Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays,”Anti-Cancer Drugs 6:522-532, 1995.
Dent et al., “Self-reactive γδ T cells are eliminated in the thymus,”Nature 343:714-719, Feb. 22, 1990.
Eisenberg et al., “Male Determined Accelerated Autoimmune Disease in BXSB Mice: Transfer by Bone Marrow and Spleen Cells,”The Journal of Immunology 125(3): 1032-1036, Sep. 1980.
Espinos et al., “Cooperation between Phosphorylation and Acetylation Processes in Transcriptional Control,”Molecular and Cellular Biology 19(5): 3474-3484, May 1999.
Espinos and Weber, “Activation of the MAP kinase cascade by histone deacetylase inhibitors is required for the stimulation of choline acetyltransferase gene promoter,”Molecular Brain Research 56:118-124, 1998.
Farrar et al., “Regulation of the Production of Immune Interferon and Cytotoxic T Lymphocytes by Interleukin 2,”The Journal of Immunology 126(3): 1120-1125, Mar. 1981.
Ferguson and Green, “T cells are just dying to accept grafts,”Nature Medicine 5(11): 1231-1232, Nov. 1999.
Finnin et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors,”Nature 401:188-193, Sep. 9, 1999.
Geller, R.L., “Role of Cross-Linking in Stepwise Activation of T Cells,”Scand. J. Immunol. 35:327-334, 1992.
Grewal and Flavell, “CD40 and CD154 in Cell-Mediated Immunity,”Annu. Rev. Immunol. 16:111-135, 1998.
Grozinger et al., “Three proteins define a class of human histone deacetylases related to yeast Hdalp,”Proc. Natl. Acad. Sci. USA 96:4868-4873, 1999.
Hara et al., “Human T Cell Activation II. A New Activation Pathway Used by a Major T Cell Population Via a Disulfide-bonded Dimer of a 44 Kilodalton Polypeptide (9.3 Antigen),”J. Exp. Med. 161:1513-1524, Jun. 1985.
Harding et al., “CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones,”Nature 356:607-609, Apr. 16, 1992.
Hassig et al., “A role for histone deacetylase activity in HDAC1-mediated transcriptional repression,”Proc. Natl. Acad. Sci. USA 95:3519-3524, Mar. 1998.
Henderson et al., “Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production,”Immunology 73:316-321, 1991.
Hojo et al., “Cyclosporine induces cancer progression by a cell-autonomous mechanism,”Nature 397:530-534, Feb. 11, 1999.
Holtrop et al., “Removal of monocytes from cell suspensions with anti-CD14 antibody and carbonyl-iron, using FcγR-dependent accessory function as a sensitive measure of monocyte presence,”Journal of Immunological Methods 156:217-222, 1992.
Hu et al., “Kinetics of interferon-γ secretion and its regulatory factors in the early phase of acute graft-versus-host disease,”Immunology 98:379-385, 1999.
Huang and Kadonaga, “Biochemical Analysis of Transcriptional Repression by Drosophila Histone Deacetylase 1,”J. Biol. Chem. 276(16): 12497-12500, Apr. 2001.
Isoniemi, H., “New Trends in Maintenance Immunosuppression,”Annales Chriurgiae et Gynaecologiae 86(2): 164-170, 1997.
Kaufman et al., “Xenotransplantation,”Annu. Rev. Immunol. 13:339-367, 1995.
Kelley et al., “Cloned Human Interferon-γ, But Not Interferon-β or -α, Induces Expression of HLA-DR Determinants by Fetal Monocytes and Myeloid Leukemic Cell Lines,”The Journal of Immunology 132(1): 240-245, Jan. 1984.
Kim et al., “Mechanism of Cell Cycle Arrest Caused by Histone Deacetylase Inhibitors in Human Carcinoma C
Lambkin Deborah C.
Seed IP Law Group PLLC
XCYTE Therapies, Inc.
LandOfFree
Depsipeptide and congeners thereof for use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Depsipeptide and congeners thereof for use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Depsipeptide and congeners thereof for use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634983